The Nordic Countries represent a unique opportunity when it comes to healthcare; boasting a wealth of data, some of the most advanced HealthTech, and being host to world leading biotech and pharma companies and universities. As such it is little surprise that the precision medicine revolution is creating such a buzz; disruptive technology, a strong economic setting and decades of social and health data collection are coming together to create the perfect storm for the future of healthcare in the region. **Nordic Precision Medicine Forum** will bring together those at the very forefront of precision medicine from biologists, physicians and technology developers to data scientists, patient groups, governments and diagnostics manufacturers.

---

**Featuring 30+ expert speakers including:**

- **Olli Kallioniemi**, Professor Director, SciLifeLab
- **Finn Cilius Nielsen**, Professor, Head of Genomic Medicine, Centre for Genomic Medicine, Rigshospitalet - Copenhagen University Hospital
- **Dag Undlien**, Professor, Head of Dept. of Medical Genetics, Oslo University Hospital
- **Kim Kjøller**, EVP Global Research & Development, LEO Pharma
- **Søren Brunak**, Professor, NNF Center for Protein Research, University of Copenhagen
- **Anders Metspalu**, Full professor of Biotechnology and Director Estonian Genome Center, University of Tartu
- **Prof Sue Hill OBE**, Chief Science Officer, NHS England
- **Mathias Uhlen PHD**, Professor, KTH Royal Institute of Technology
- **Morten Mau-Serensen**, Chief Physician at the Phase I unit, Department of Oncology, Rigshospitalet, Copenhagen, Denmark: President of the Danish Association for Cancer Research and a member of the Danish Health Medical Agency’s panel on experimental therapy
- **Torben Falck Ørntoft**, Professor, Chief Consultant, Head of Department Molecular Medicine, Aarhus University Hospital
- **Morten Sogaard**, Ph.D, Vice President and Head, WRD Genome Sciences & Technologies, Worldwide R&D, Pfizer, Inc.
- **Paul Franks**, Professor and Deputy Director of Lund University Diabetes Center in Sweden, Head of Genetic & Molecular Epidemiology Unit

---

**Platinum sponsor:**

**Premier sponsor:**

**Associate sponsor:**

---

www.precisionmedicineforum.com
### 26 April 2017

**8.00** Registration and welcome coffee

**8.55** Chairs Opening remarks:
- Henrik Ullum MD, PhD, Professor in clinical immunology at Institute for Clinical Medicine, University of Copenhagen and Chief Physician at Department of Clinical Immunology, Rigshospitalet, where he serves as head of The Copenhagen Biobank Unit and The Virology Section.

**9.00** Opening Plenary

Annamarie Lauritsen, Deputy Permanent Secretary, Ministry of Health Denmark

Maj-Britt Juhi Poulsen, Executive Adviser, Team Leader, PhD Health Technology, Business Relations and Regional Development, Danish Regions

Dr Jaakko Yrjö Koskinen, Ministerial Counsellor at the Social and Health Services Department of the Ministry of Social Affairs and Health of Finland

**10.00** Precision Medicine Thought Leaders – setting the scene for the future of healthcare:

Olli Kallioniemi, Professor of Molecular Precision Medicine at the Karolinska Institutet and Director of the Science for Life Laboratory

Morten Søgaard, PhD, Vice President and Head, WRD Genome Sciences & Technologies, Worldwide R&D, Pfizer Inc.

Prof Sue Hill OBE, Chief Science Officer, NHS England

**11.00** Refreshments and Networking

---

### Track 1

**Disease Areas; Oncology and Beyond**

**Chair:** Henrik Ullum MD, PhD

**11.30-11.45** How Precision Medicine Impacts Drug Development from a CNS Perspective

- A historical perspective
- The impact of a high placebo response
- Disease modification and consequences
- Less acceptance of non-response
- Safety and tolerability aspects

Birgitte Søgaard, Divisional Director Clinical & Quantitative Pharmacology, H. Lundbeck A/S

**11.45-12.00** Personalized medicine with the patient in focus: providing patient stratification for prevention, screening, diagnosis, treatment and follow-up; examples mainly from cancer.

- Genotyping and use of biomarkers can address all steps in the disease and prevention process.
- A national initiative with the patient in focus is needed to cover all Danish Citizens
- The PerMed process can benefit patients from early on, and also houses the potential for better disease understanding, and is a continuous learning process for all involved including bioinformaticians, molecular biologists, medical doctors and ethical/legal staff.

Professor Torben Brønnum, Consultant in Molecular Medicine, Aarhus University

**12.00-12.15** Precision Medicine applications in Dermatology:

Kim Kjeller, Executive Vice President Global R&D, LEO Pharma A/S

**12.15-12.30** Precision Oncology: the war against cancer

Morten Mau-Sørensen, Chief Physician at the Phase I unit, Department of Oncology, Rigshospitalet, Copenhagen. President Danish Association for Cancer Research

**12.30-12.45** How can IBM’s Watson help achieve the goals of precision medicine

IBM’s Watson is helping both life science companies and oncologists around the world in achieving the goals of precision medicine. In this presentation you will hear how Watson is helping researchers in life science companies develop new drugs and oncologists in finding personalized treatments or clinical trials for the individual patient through the use of cognitive computing.

Peter Mortensen, Watson Health Executive, IBM

---

### New Speakers are being added daily

Please check www.precisionmedicineforum.com/nordic2017 for the latest programme

---

### Lifestyle and prevention in the context of Precision Medicine – how do we help prevent people from becoming patients

**16.00-16.15**
- Lifestyle interventions generally improve cardiometabolic health, but one size does not fit all
- The between-person variability in response to lifestyle interventions has multiple possible explanations, one of which is that individual biological factors modify the effects of such interventions
- Characterising patients’ biological profiles and linking these to response phenotypes might lead to the optimization of lifestyle interventions

Paul Franks, Professor and Deputy Director of Lund University Diabetes Center in Sweden, Head of Genetic & Molecular Epidemiology Unit

**16.15-16.30** From biobanking to precision medicine: An Estonian case

- The design of the population based biobank in Estonia in year 2000
- Linking the data from the EMR to the biobank participants, getting the “life-long disease trajectories”
- Producing the OMICS data (we have all 52 000 people from the biobank genotyped when the meeting starts)
- Producing the Estonian reference whole genome sequence (30x) database of 2 500 people and imputing the array data
- Delivering the information back to the people using the “genetics first” principle
- Complex disease (T2D, CAD)
- Pharmacogenetics
- Incidental findings
- Estonian program for the precision medicine 2017-2022
- Conclusions

Andres Metspalu, M.D., PhD. Professor and Director of the Estonian Genome Center, University of Tartu

**16.30-16.45** How can biobanks support precision medicine?

Estrid Hegdall, Clinical professor in molecular pathology at University of Copenhagen and Head of Molecular Unit, Department of Pathology

**16.45-17.00** Panel discussion

**17.00** Networking Drinks Reception

---
### Track 2

**Clinical Implementation of Precision Medicine - Bringing Genomics into mainstream Healthcare**

*Chair: Dr Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30-11.50</td>
<td>Multiplex protein analysis of biomarkers in atherosclerosis</td>
<td>Development of atherosclerotic plaque vulnerability involves an accumulation of cytoplasmic lipids, an inflammation-driven degradation of the plaque extracellular matrix and a loss of cells with repair function. There is a clinical need for good circulating biomarkers that reflect these processes. While different types of inflammatory biomarkers have been extensively studied biomarkers reflecting cell death as well as extracellular matrix degradation and repair are less well characterized. We have recently shown that accumulation of apoptotic cell death is associated with a release of soluble death receptors such as Fas and TRAIL receptor 2 that can be measured in plasma. Using the proximity extension assay-based OLINK cardiovascular disease panel we could demonstrate that subjects with high plasma levels of death receptors have an increased risk of cardiovascular disease. Moreover, an increased risk is also observed in subjects with high levels of the matrix metalloproteinases MMP-7 and -12 as well as in subjects low levels of growth factors for vascular smooth muscle cells and vascular progenitor cells. These observations provide clinical support for an important role of vascular injury and repair in the development of cardiovascular disease. Indeed, there is evidence that impaired repair vascular is a key factor in cardiovascular complications to diabetes.</td>
</tr>
<tr>
<td>Jan Nilsson, Department of Clinical Sciences Malmö, Lund University</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.50-11.05</td>
<td>This talk will cover:</td>
<td>The talk will cover:</td>
</tr>
<tr>
<td></td>
<td><em>Standardization of NGS Diagnostics.</em></td>
<td>- Why is it necessary and how to do it?</td>
</tr>
<tr>
<td></td>
<td><em>Secondary usage of genome data: Why is it important?</em></td>
<td>- Data sharing.</td>
</tr>
<tr>
<td></td>
<td><em>Informed consent as an enabler of personalized medicine.</em></td>
<td>- Why is it important and how can we make it become a reality?</td>
</tr>
<tr>
<td></td>
<td><em>Multi-omics tools in precision medicine</em></td>
<td>- Informed consent as an enabler of personalized medicine.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.05-12.20</td>
<td>Implementing WGS in routine diagnostic settings</td>
<td>Valtteri will discuss the technical aspects of implementing WGS in routine diagnostic settings, and exemplifying this using rare disease diagnostics. How are we achieving the turnaround time and quality required for diagnostic testing, as well as the clinical decision support tools we have developed. This would include quick overview of how we use HPO terms to guide analysis. The goal of all of this is to make WGS the first-line diagnostic test for cases suspected of having a rare genetic disorder.</td>
</tr>
<tr>
<td></td>
<td>Valtteri Wirta, Ph.D., Head of Clinical Genomics facility at Science for Life Laboratory</td>
<td></td>
</tr>
</tbody>
</table>

*New speakers are being added daily*


---

**Partnerships in Precision Medicine**

14.40-15.00

Enabling innovation in precision medicine through partnerships

- Today it is impossible to build all the competencies internally. Companies need to partner to gain access to:
  - cutting edge technologies
  - world class experience and knowledge
  - competences not found within the organization

This talk will give examples of how the LED Science & Tech Hub is building this network in Cambridge (USA)

Michael Sierra, PhD, Vice President LED Science & Tech Hub

15.00-15.20

Collaboration as a Path to Precision Medicine in Major Depressive Disorder:

- Expertise with biobank samples in Depression
- Thinking differently
- Working differently

Jennifer Larsen, PhD, Systems Biology Specialist, Clinical Pharmacology, H. Lundbeck

15.20-15.40

Coffee

16.00-16.15

Precision Diagnostics a prerequisite for Precision Medicine in complex disease

Prof. Carl A.K. Borrebaek, Department of Immunotechnology, and Director of CREATE Health – Lund University

16.15-16.30

Comparison Diagnostics – recent advances and future perspectives

Comparison Diagnostics have evolved in recent years and will continue to do so based on the evolving regulatory landscape, the emergence of new technologies, and the development of new concepts. This progress will be imperative to the future development of precision medicine

Dr Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting

---

**Multi Omics Technologies – standalone or working together?**

16.30-16.45

The SCAPIS SilkLab Wellness Profiling program The Human Protein Atlas (www.proteinatlas.org) has launched a Tissue Atlas (2014), a Cell Atlas (2016) and will launch a Pathology Atlas in 2017. The resources created within this program has been used to launch the SCAPIS SilkLab Wellness Profiling project with extensive integration of imaging data with classical diagnostics and omics-based analysis in which individuals are followed by repeated analysis every third months.

Mathias Uhlén Ph.D., Professor, KTH Royal Institute of Technology

16.45-17.00

Metabolomics - a yet underevaluated tool in precision medicine and nutrition

- The metabolome, i.e. the pool of metabolites in a biological system represents a snapshot of the final molecular readout of what has been encoded by the genome, modified by foods, drugs pollutants, gut microbiota and it provides information about the metabolic state of an individual.
- Metabolomics signatures of the metabolome are expected not only to provide improved predictive, prognostic, diagnostic and surrogate markers of different disease and health states, but also to provide insights of underlying mechanisms of disease and further allow discovery of biomarkers of intervention response phenotypes.
- Metabolomics to provide comprehensive information of individuals’ metabolic state, is a yet under-explored tool in precision medicine and nutrition.
- Analytical platforms and data handling pipelines have recently been developed, also in the Nordic countries, which makes it possible to measure thousands of metabolite in biological samples.
- Examples and ideas of how metabolomics data can be used to define variation in responses to treatment and thus provide a powerful tool for precision medicine and nutrition will be given.

Rikard Landberg, Professor of Food and Health, Chalmers University of Technology

17.00

Networking Drinks Reception

---

Please note each session will include a panel discussion so as to allow plenty of time for questions.
Choose Your Delegate Package:

**Conference Rate:**
All prices are + local VAT at the prevailing rate

**Standard Rate:**
€560

**Academia/Healthcare:**
€480

**Fee includes:**
- Conference Pass
- Delegate Programme
- Buffet lunch, snacks and refreshments throughout the conference
- Complimentary Networking Drinks Reception

*Please note academic/healthcare registrations are subject to approval

---

How to Register:

1. Online through our secure portal. Register and pay online [www.precisionmedicineforum.com](http://www.precisionmedicineforum.com) (you will need your payment card to complete registration)

2. Complete the registration form [www.precisionmedicineforum.com](http://www.precisionmedicineforum.com) and we will send an invoice (please note your place is not confirmed until full payment is received)

3. Phone: +44 (0)1273 931616

4. Email: register@precisionmedicineforum.com

---

**Venue:**

**Tivoli Hotel and Congress Center**
Accommodation is not included in the registration fee.

For reservations please contact the hotel directly: [www.tivolihotel.com](http://www.tivolihotel.com)

Arni Magnusson Gade 2
DK-1577 København V
Tel. +45 4487 0000
tivolihotel@arp-hansen.dk

---

**Why Sponsor Nordic Precision Medicine Forum 2017**

We believe that connecting with other leading minds is the best way to grow your brand and business.

Attendees come to us for content and the long-lasting connections they make.

The format of Precision Medicine Forum offers a unique environment to make new connections, share ideas and formulate partnerships for future collaboration. As a sponsor we work with you to ensure that your objectives are met by building bespoke packages. These can range from exhibition stands to hosting workshops, sponsorship of gala dinners to playing your corporate video during a break.

- Build your brand presence
- Demonstrate your expertise and thought leadership
- Showcase your products and services
- Generate new business leads
- Align yourself with the leading organisations in the Precision Medicine arena

Don’t forget, – it’s not just about the conference itself. As a sponsor you’ll be afforded considerable marketing exposure across a whole variety of channels before, during and post event through Precision Medicine Forum online, via our social media and affiliates.

---

For further information please contact us: marketing@precisionmedicineforum.com
Tel: +44 (0)1273 931616